Gambaran Umum
Immatics N.V., based in Germany, operates in the biotechnology sector with a specialized focus on the discovery and development of T cell redirecting cancer immunotherapies. The company leverages its proprietary XPRESIDENT and TCR discovery platforms to identify novel tumor targets and develop T-cell receptor-based therapeutics. Notably, Immatics is advancing a diverse pipeline of treatments through both proprietary and partnered development programs. Key projects include TCR-based therapies such as IMA201 and IMA202, targeting solid tumors, which are in clinical development stages. Immatics aims to transform the clinical landscape of cancer treatment by harnessing the body’s own immune system to fight tumor cells more effectively. This innovative approach positions Immatics N.V. as a prominent player in immunotherapy within the biotech industry.
Skor Kualitas, Nilai, dan Momentum
Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.
Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
- Nilai revenue untuk Immatics N.V. per 2025 Jun 30 adalah 130.13 MM.
- Nilai operating income untuk Immatics N.V. per 2025 Jun 30 adalah -87.08 MM.
- Nilai net income untuk Immatics N.V. per 2025 Jun 30 adalah -74.75 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-06-30 | 130.13 | -87.08 | -74.75 |
2025-03-31 | 144.15 | -60.52 | -22.40 |
2024-12-31 | 155.84 | -38.62 | 15.22 |
2024-09-30 | 115.50 | -67.23 | -55.79 |
2024-06-30 | 70.87 | -101.01 | -73.71 |
2024-03-31 | 74.47 | -88.76 | -77.14 |
2023-12-31 | 54.00 | -101.72 | -94.65 |
2023-09-30 | 75.72 | -73.97 | -84.08 |
2023-06-30 | 84.86 | -62.62 | -78.53 |
2023-03-31 | 79.72 | -64.97 | -67.89 |
2022-12-31 | 172.83 | 29.95 | 27.70 |
2022-09-30 | 150.91 | 13.85 | 33.96 |
2022-06-30 | 142.29 | 12.77 | 27.69 |
2022-03-31 | 130.27 | 6.04 | 15.14 |
2021-12-31 | 34.76 | -86.29 | -93.33 |
2021-09-30 | 28.48 | -90.27 | -94.52 |
2021-06-30 | 29.91 | -90.57 | -231.28 |
2021-03-31 | 31.62 | -82.27 | -225.79 |
2020-12-31 | 31.25 | -69.72 | -211.28 |
2020-09-30 | 26.19 | -61.97 | -208.03 |
Laporan Laba Rugi: EPS
- earnings per share basic untuk Immatics N.V. pada 2025 Jun 30 adalah -0.64.
- laba per saham yang terdilusi untuk Immatics N.V. pada 2025 Jun 30 adalah -0.65.
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-06-30 | -0.64 | -0.65 |
2025-03-31 | -0.20 | -0.20 |
2024-12-31 | 0.14 | 0.14 |
2024-09-30 | -0.57 | -0.61 |
2024-06-30 | -0.80 | -0.79 |
2024-03-31 | -0.90 | -0.91 |
2023-12-31 | -1.18 | -1.18 |
2023-09-30 | -1.08 | -1.08 |
2023-06-30 | -1.06 | -1.06 |
2023-03-31 | -0.96 | -0.96 |
2022-12-31 | 0.41 | 0.40 |
2022-09-30 | 0.53 | 0.53 |
2022-06-30 | 0.44 | 0.43 |
2022-03-31 | 0.24 | 0.24 |
2021-12-31 | -1.48 | -1.48 |
2021-09-30 | -1.50 | -1.50 |
2021-06-30 | -3.26 | -3.26 |
2021-03-31 | -4.07 | -4.07 |
2020-12-31 | -4.40 | -4.40 |
2020-09-30 | -5.13 | -5.13 |
Arus Kas: Operasi, Investasi, Pendanaan
- Nilai cash from operating activities untuk Immatics N.V. per 2025 Jun 30 adalah -165.47 MM.
- Nilai cash from investing activities untuk Immatics N.V. per 2025 Jun 30 adalah 130.66 MM.
- Nilai kas dari aktivitas pendanaan untuk Immatics N.V. per 2025 Jun 30 adalah 144.14 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-06-30 | -165.47 | 130.66 | 144.14 |
2025-03-31 | -159.63 | 136.24 | 144.30 |
2024-12-31 | -158.03 | -152.39 | 319.68 |
2024-09-30 | -20.48 | -45.24 | 172.35 |
2024-06-30 | -17.27 | -182.83 | 223.01 |
2024-03-31 | 9.34 | -269.49 | 260.03 |
2023-12-31 | 18.23 | -31.39 | 84.52 |
2023-09-30 | -92.30 | -181.33 | 190.98 |
2023-06-30 | -93.91 | -181.82 | 144.09 |
2023-03-31 | -30.97 | -219.35 | 123.53 |
2022-12-31 | 100.13 | -209.79 | 123.71 |
2022-09-30 | 102.00 | -121.42 | 17.64 |
2022-06-30 | 118.54 | -30.73 | 13.94 |
2022-03-31 | 43.98 | 10.77 | -2.82 |
2021-12-31 | -84.75 | 7.49 | -2.61 |
2021-09-30 | -80.92 | 8.92 | -1.88 |
2021-06-30 | -127.33 | -4.87 | 207.70 |
2021-03-31 | -90.82 | 5.83 | 208.01 |
2020-12-31 | -80.70 | -15.95 | 207.88 |
2020-09-30 | -31.27 | -32.34 | 207.27 |
Metrik Penilaian: PE, PriceToBook, PriceToTBV
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-06-30 | |||
2025-03-31 | |||
2024-12-31 | |||
2024-09-30 | |||
2024-06-30 | |||
2024-03-31 | |||
2023-12-31 | |||
2023-09-30 | |||
2023-06-30 | |||
2023-03-31 | |||
2022-12-31 | |||
2022-09-30 | |||
2022-06-30 | |||
2022-03-31 | |||
2021-12-31 | |||
2021-09-30 | |||
2021-06-30 | |||
2021-03-31 | |||
2020-12-31 | |||
2020-09-30 |
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-06-30 | ||
2025-03-31 | ||
2024-12-31 | ||
2024-09-30 | ||
2024-06-30 | ||
2024-03-31 | ||
2023-12-31 | ||
2023-09-30 | ||
2023-06-30 | ||
2023-03-31 | ||
2022-12-31 | ||
2022-09-30 | ||
2022-06-30 | ||
2022-03-31 | ||
2021-12-31 | ||
2021-09-30 | ||
2021-06-30 | ||
2021-03-31 | ||
2020-12-31 | ||
2020-09-30 |
Efektivitas Manajemen
- roa untuk Immatics N.V. pada 2025 Jun 30 adalah -0.04.
- roe untuk Immatics N.V. pada 2025 Jun 30 adalah -0.06.
- roic untuk Immatics N.V. pada 2025 Jun 30 adalah -0.04.
- croic untuk Immatics N.V. pada 2025 Jun 30 adalah 0.22.
- ocroic untuk Immatics N.V. pada 2025 Jun 30 adalah -0.29.
Period End (TTM) | ROA | ROE | ROIC (Tingkat Pengembalian Investasi Modal) | CROIC | OCROIC |
2025-06-30 | -0.04 | -0.06 | -0.04 | 0.22 | -0.29 |
2025-03-31 | 0.02 | 0.04 | 0.03 | 0.03 | -0.27 |
2024-12-31 | -0.11 | -0.25 | -0.14 | 0.27 | -0.05 |
2024-09-30 | -0.17 | -0.30 | -0.18 | 0.07 | -0.04 |
2024-06-30 | -0.21 | -0.40 | -0.19 | 0.01 | 0.02 |
2024-03-31 | -0.24 | -0.46 | -0.40 | 0.29 | 0.08 |
2023-12-31 | -0.24 | -0.74 | -0.32 | -0.36 | -0.35 |
2023-09-30 | -0.21 | -0.63 | -0.33 | -0.57 | -0.37 |
2023-06-30 | -0.18 | -0.54 | -0.33 | -0.57 | -0.37 |
2023-03-31 | 0.13 | 0.32 | -0.32 | -0.60 | -0.14 |
2022-12-31 | 0.17 | 0.97 | 0.26 | 0.13 | 0.84 |
2022-09-30 | 0.14 | 0.79 | 0.26 | 0.13 | 0.84 |
2022-06-30 | 0.07 | 0.20 | 0.20 | 0.74 | 0.82 |
2022-03-31 | -0.39 | -1.23 | 0.12 | 0.42 | 0.33 |
2021-12-31 | -0.44 | -1.08 | -2.75 | -2.20 | -1.92 |
2021-09-30 | -0.40 | -2.01 | -2.66 | -1.72 | -1.13 |
2021-06-30 | -2.27 | -2.94 | 0.89 | -1.13 | |
2021-03-31 | -2.00 | -2.97 | 1.50 | -1.11 | |
2020-12-31 | -1.57 | -1.91 | 0.94 | -0.78 | |
2020-09-30 | -1.72 | 1.10 | -0.27 |
Gross Margins
- marjin kotor untuk Immatics N.V. pada 2025 Jun 30 adalah -0.10.
- marjin bersih untuk Immatics N.V. pada 2025 Jun 30 adalah -0.16.
- marjin operasi untuk Immatics N.V. pada 2025 Jun 30 adalah -0.42.
- Margin Kotor
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Margin Keuntungan Bersih
- Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
- Margin Operasi
- Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
Period End (TTM) | Margin Kotor | Margin Keuntungan Bersih | Margin Operasi |
2025-06-30 | -0.10 | -0.16 | -0.42 |
2025-03-31 | 0.05 | 0.10 | -0.25 |
2024-12-31 | -0.21 | -0.48 | -0.58 |
2024-09-30 | -0.88 | -1.04 | -1.43 |
2024-06-30 | -0.65 | -1.08 | -1.19 |
2024-03-31 | -1.20 | -1.80 | -1.88 |
2023-12-31 | -0.50 | -1.11 | -0.98 |
2023-09-30 | -0.31 | -0.93 | -0.74 |
2023-06-30 | -0.37 | -0.93 | -0.74 |
2023-03-31 | 0.38 | -0.85 | -0.81 |
2022-12-31 | 0.32 | 0.23 | 0.09 |
2022-09-30 | 0.34 | 0.23 | 0.09 |
2022-06-30 | 0.31 | 0.19 | 0.09 |
2022-03-31 | -1.52 | 0.12 | 0.05 |
2021-12-31 | -2.00 | -2.68 | -2.48 |
2021-09-30 | -1.73 | -3.94 | -3.17 |
2021-06-30 | -1.73 | -8.20 | -2.88 |
2021-03-31 | -1.46 | -7.70 | -2.60 |
2020-12-31 | -1.15 | -6.76 | -2.23 |
2020-09-30 | -1.23 | -8.44 | -2.19 |
Pengenal dan Deskriptor
Kunci Indeks Pusat (CIK) | 1809196 |
Grupong Pang-industriya
SIC 2836 - Biological Products, Except Diagnostic Substances (Biotech) |